4 completed, 3 unknown, 1 terminated, 1 withdrawn. 8 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Unknown 3, Terminated 1 |
| Phase 3 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Perhexiline: new trials by email Literature Review of Perhexiline trials Research Report on Perhexiline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Perhexiline in Hypertrophic Cardiomyopathy Perhexiline, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Unknown | Flinders University | 60 | 2020-12-01 | 2021-03-11 |
| Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline - Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial | Phase 2 | Terminated | Heart Metabolics Limited | 35 | 2016-08-01 | 2017-08-31 |
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Perhexiline, Placebo marked PEXSIG - Myocardial Reperfusion Injury, Cardiac Output, Low | Phase 2 / Phase 3 | Unknown | University Hospital Birmingham | 220 | 2009-10-01 | 2011-08-11 |
| Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome Perhexiline, Placebo - Diastolic Heart Failure | Phase 2 | Completed | University of Aberdeen | 70 | 2009-03-01 | 2015-11-05 |
| Metabolic Manipulation in Chronic Heart Failure Perhexiline, Placebo - Chronic Heart Failure | Phase 2 | Completed | University Hospital Birmingham NHS Foundation Trust | 50 | 2009-02-01 | 2011-11-29 |
| Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery Perhexiline, Placebo marked PEXSIG - Myocardial Reperfusion Injury, Cardiac Output, Low | Phase 2 / Phase 3 | Completed | University Hospital Birmingham | 290 | 2007-02-01 | 2010-05-20 |
| Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy Perhexiline/Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | University Hospital Birmingham | 44 | 2006-12-01 | 2010-11-04 |
| Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes Perhexiline - Diabetic Cardiomyopathy | Phase 1 / Phase 2 | Unknown | University Hospital Birmingham | 75 | 2006-10-01 | 2008-03-04 |
| Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure Perhexiline, Placebo - Hypertrophic Cardiomyopathy | Phase 3 | Withdrawn | Heart Metabolics Limited | 2017-07-14 |
Cardiomyopathy, Hypertrophic (4) · Cardiac Output, Low (2) · Heart Failure (2) · Myocardial Reperfusion Injury (2) · Aortic Valve Stenosis (1) · Cardiomyopathy, Dilated (1) · Cardiomyopathy, Hypertrophic, Familial (1) · Diabetes Mellitus (1) · Diabetic Cardiomyopathies (1) · Heart Failure, Diastolic (1) · Hypertrophy (1) · Hypertrophy, Left Ventricular (1)
University Hospital Birmingham (4) · Heart Metabolics Limited (2) · Flinders University (1) · University Hospital Birmingham NHS Foundation Trust (1) · University of Aberdeen (1)
United Kingdom (6) · Australia (1) · United States (1)
Domeinco Pagano, MD FRCS (2) · Michael P Frenneaux, MBBS MD (2) · Joseph Selvanayagam (1) · Mark Midei, MD (1) · Michael Frenneaux, MD (1) · Michael Frenneaux, MD FRCP FACC (1) · Rajiv Ananthakrishna (1) · Roger M Beadle, MBBS (1)
PMID 20921440, PMID 21645332, PMID 24948413, PMID 25495811, PMID 25650370
2004 (1)